114P RATIONALE-315: Association of residual viable tumor (RVT) and nodal status with survival benefit for patients (pts) with resectable non-small cell lung cancer (NSCLC) treated with perioperative tislelizumab (TIS)

G. Schvartsman; D. Yue; M. Provencio Pulla; H. Liu; L. Liu; G. Han; L. Zhang; K. Naicker; N. Zhao; X. Lin; M. Austin Taylor; S. Peters; L. Cao; C. Wang

doi:10.1016/j.esmoop.2026.106421

March 17, 2026ESMO OpenOpen Access

114P RATIONALE-315: Association of residual viable tumor (RVT) and nodal status with survival benefit for patients (pts) with resectable non-small cell lung cancer (NSCLC) treated with perioperative tislelizumab (TIS)

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to explore the impact of residual viable tumor and nodal status on survival in resectable non-small cell lung cancer patients treated with tislelizumab.
Conducted a retrospective analysis of patients with resectable non-small cell lung cancer.
Assessed the correlation between residual viable tumor and nodal status with patient survival.
Evaluated the effects of perioperative tislelizumab treatment.
Patients with lower residual viable tumor had improved survival rates.
Nodal status was a significant predictor of patient outcomes.
T-cell functionality was associated with durable treatment benefits.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

This analysis associates residual viable tumor and nodal status with survival benefit in patients with resectable non-small cell lung cancer, suggesting improved treatment strategies.

Abstract

m on Q6W combo (p<0.1;n=10), indicating better T-cell functionality in patients with durable benefit. Conclusions:These translational results indicate biological and clinical activity of acasunlimab + pembro in PD-L1+ mNSCLC, supporting a less frequent dosing paradigm (Q6W) to reinvigorate and maintain T-cell functionality post-CPI.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Schvartsman et al. (2026) studied this question.

synapsesocial.com/papers/69be34d16e48c4981c672efc https://doi.org/10.1016/j.esmoop.2026.106421

View Full Paper

Ask AI

Bookmark

Share

114P RATIONALE-315: Association of residual viable tumor (RVT) and nodal status with survival benefit for patients (pts) with resectable non-small cell lung cancer (NSCLC) treated with perioperative tislelizumab (TIS)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

114P RATIONALE-315: Association of residual viable tumor (RVT) and nodal status with survival benefit for patients (pts) with resectable non-small cell lung cancer (NSCLC) treated with perioperative tislelizumab (TIS)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading